PSP Research LLC Buys Shares of 5,244 Celcuity, Inc. $CELC

PSP Research LLC bought a new stake in Celcuity, Inc. (NASDAQ:CELC) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 5,244 shares of the company’s stock, valued at approximately $523,000.

Other hedge funds also recently added to or reduced their stakes in the company. Ogorek Anthony Joseph NY ADV bought a new stake in Celcuity in the third quarter valued at $27,000. US Bancorp DE raised its stake in shares of Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after purchasing an additional 143 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of Celcuity by 78.9% during the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after purchasing an additional 1,167 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Celcuity by 211.2% during the second quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company’s stock valued at $74,000 after purchasing an additional 3,766 shares in the last quarter. Finally, NBC Securities Inc. bought a new stake in shares of Celcuity during the fourth quarter valued at about $99,000. 63.33% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Needham & Company LLC restated a “buy” rating and set a $157.00 price objective on shares of Celcuity in a research note on Friday, May 15th. Citizens Jmp lifted their price objective on shares of Celcuity from $150.00 to $160.00 and gave the company a “market outperform” rating in a research note on Monday, May 4th. Wall Street Zen cut shares of Celcuity from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Wolfe Research restated an “outperform” rating and set a $110.00 price objective on shares of Celcuity in a research note on Thursday, March 12th. Finally, Craig Hallum restated a “buy” rating and set a $189.00 price objective on shares of Celcuity in a research note on Monday, May 4th. Eleven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $149.30.

Celcuity Price Performance

NASDAQ:CELC opened at $131.09 on Wednesday. The business’s 50-day moving average price is $119.52 and its 200 day moving average price is $107.75. The firm has a market cap of $6.39 billion, a P/E ratio of -33.61 and a beta of 0.09. Celcuity, Inc. has a 52-week low of $10.26 and a 52-week high of $151.02. The company has a quick ratio of 12.31, a current ratio of 12.31 and a debt-to-equity ratio of 6.04.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.10. As a group, sell-side analysts predict that Celcuity, Inc. will post -3.87 earnings per share for the current fiscal year.

Insider Transactions at Celcuity

In other Celcuity news, Director David Dalvey sold 25,000 shares of the firm’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the completion of the sale, the director directly owned 65,000 shares in the company, valued at approximately $9,144,200. This trade represents a 27.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of Celcuity stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $140.46, for a total value of $1,264,140.00. Following the sale, the director owned 6,760 shares of the company’s stock, valued at approximately $949,509.60. This represents a 57.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 37,000 shares of company stock valued at $5,111,950 over the last 90 days. Corporate insiders own 13.33% of the company’s stock.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.